FON-2021-0899 Journal Article Infographic.pdf (973 kB)

FON-2021-0899 Infographic – Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003

figure

posted on 2021-11-16, 11:57 authored by Tae Won Kim, Julien Taieb, Ellen B Gurary, Nati Lerman, Karen Cui, Takayuki Yoshino

Infographic: Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., NJ, USA, and AstraZeneca

History

Usage metrics

Read the peer-reviewed publication

Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003

Future Oncology

Categories

Oncology and carcinogenesis not elsewhere classified

Keywords

5-fluorouracil bevacizumab colorectal cancer FOLFOX folinic acid irinotecan maintenance therapy olaparib oxaliplatin PARP inhibitor Cancer

Licence

CC BY-NC-ND 4.0

Exports